This editorial refers to 'Impact of statin therapy on coronary plaque burden and composition assessed by coronary computed tomographic angiography: a systematic review and meta-analysis' by L. Andelius et al., 
Introduction
Current evidence is robust about the primary role of cardiac computed tomography (CCT) as diagnostic tool for the detection of suspected obstructive coronary artery disease (CAD). Updated 2017 guidelines of the National Institute for Health and Care Excellence (NICE) from the UK NHS regarding the approach in the detection of suspected obstructive CAD put computed tomography (CT) as the first imaging tool in these settings. 1 Evidence is building also on the fact that stable obstructive CAD should not mandatorily be approached with revascularization. In fact, obstructive CAD is not a disease but rather a complication of atherosclerosis. Previous studies already showed that medical therapy could deliver results comparable with percutaneous coronary intervention (PCI) in stable patients. 2 The ORBITA trial demonstrated also the relevant placebo effect of PCI in the context of stable CAD. 3 The landscape of CAD is changing and there is a demand for, or an 'evolution towards' if you will, a more clinical (rather than mechanical) and personalised approach to CAD.
Cardiac computed tomography showed its potential in the visualization and quantification of atherosclerotic plaques since the very beginning of its development. 4, 5 The SCOT-HEART study showed that the diagnostic advantage of CCT translates into a better prognosis 6 ; the explanation is that CCT can always show and diagnose sub-clinical/non-obstructive atherosclerosis (regardless the degree of stenosis), thereby inducing a more aggressive medical therapy and more motivation for adherence to therapeutic schemes.
Hence, anti-atherosclerotic medical therapy is the key and should be optimized and individualized as much as possible also accounting for non-obstructive atherosclerotic phenotypes that can be identified using CCT.
In this issue of the Journal Andelius et al. 7 performed a metaanalysis on the impact of statin therapy on coronary plaque burden using CCT.
Morphological computed tomography-based methods to quantify and characterize atherosclerosis plaque burden-Caveats
Currently, there is no methodology and/or software platform that is widely recognized or accepted to quantify and characterize atherosclerotic plaque burden and its features with CCT. Surely, there was no unique methodology when the studies of the meta-analysis from Andelius et al. 7 were performed. Several technical and physiological factors can affect the measurements in terms of quantification of plaque burden using CCT, thereby affecting reproducibility and comparability of results. 8, 9 For instance, reconstruction algorithms are different between different CT vendors and also, within the same vendor, between different software releases. Also, there is a consistent impact of intravascular attenuation, related mostly to the volume and rate of intravenous contrast material administration, on the measured attenuation of non-calcified plaque components of the coronary trees. More recently more factors have to be considered, like kilovoltage modulation and iterative reconstructions algorithms. Given all these considerations, there has been an important and constant development of software application with semi-automated
The opinions expressed in this article are not necessarily those of the Editors of EHJCI, the European Heart Rhythm Association or the European Society of Cardiology. onary plaque burden with a non-invasive test (CCT) the field of (advanced) primary prevention (i.e. patients in which CAD is present but non obstructive) can become more personalized, and we could even consider that in the future, we will integrate all the information to modulate antiatherosclerotic therapies. CAD, coronary artery disease; CMR, cardiac magnetic resonance; CT, computed tomography; ECG, electrocardiogram; Echo, echocardiography; FFR, fractional flow reserve; PET, positron emission tomography; SPECT, single-photon emission computed tomography. segmentation capabilities that allow the extraction of coronary artery walls with reasonable reliability. These softwares are more reliable today as compared to some years ago (Figure 1 ).
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The patient with non-obstructive coronary artery disease Although, we see all the many current limitations of CCT for the quantification and characterization of coronary plaque burden, we should also look ahead because this is the beginning of a new possible approach to an imaging-guided personalised anti-atherosclerotic therapy.
The new PARADIGM (Progression of AtheRosclerotic PlAque DetermIned by Computed TomoGraphic Angiography IMaging) registry is focused on this aspect, which is actually the next step towards this goal. 11 Enrolling > _2000 patients who underwent at least two CCT scans and with a follow-up for adverse cardiovascular events, the PARADIGM aims at observation of the natural course of atherosclerosis and at the identification of the clinical determinants of plaque progression or regression, thereby giving tools for attenuating disease progression and improving clinical outcomes.
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Conclusions
Despite all the limitations that CCT still has for the characterization and quantification of plaque burden, there is already consistent evidence that in the near future we will be able to the assess coronary atherosclerosis and adapt our medical therapies accordingly and with a more individualized approach ( Figure 2) . Methodologies, tools and definitions are still developing, however, its probably just a question of time.
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